Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 05, 2021 07:30 ET | Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...
Does Your Mask/Respirator Filter Live Viruses?
March 23, 2021 03:00 ET | i3 BioMedical Inc.
MIRABEL, Quebec, Canada, March 23, 2021 (GLOBE NEWSWIRE) -- i3 Biomedical inc., a medical device corporation, releases today the comparative results of Live viruses Filtration performances of...
Company Logo.jpg
Vystar appoints Dr. Byron Novosad to Board of Directors
February 23, 2021 08:30 ET | Vystar Corp.
Worcester, MA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vystar® Corporation (OTCQB: VYST) has named Byron Novosad, DDS, to the Vystar Board of Directors, effective immediately. He fills the seat vacated by...
Vystar Issues Corporate Update on Strategic Initiatives and the Impact of COVID-19 on Brands
February 01, 2021 08:30 ET | Vystar Corp.
Worcester, MA, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST), parent company of RxAir® UV light air purification products, Rotmans Furniture and Floor Covering, and Vytex®...
AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
January 25, 2021 02:27 ET | AB Science
NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET...
AB Science annonce qu'une nouvelle publication indépendante confirme que le masitinib a une activité anti-virale contre le virus SARS-CoV-2 in vitro et est un candidat prometteur pour le traitement du Covid-19
January 25, 2021 02:27 ET | AB Science
UNE NOUVELLE PUBLICATION INDÉPENDANTE CONFIRME QUE LE MASITINIB A UNE ACTIVITÉ ANTI-VIRALE CONTRE LE VIRUS SARS-COV-2 IN VITRO ET EST UN CANDIDAT PROMETTEUR POUR LE TRAITEMENT DU COVID-19 Paris, le...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
January 19, 2021 17:06 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced that it will be presenting preliminary results from an ongoing SARS-CoV-2 mutation...
UK Doctor Develops ‘MAYA’ (Medical Advice You Access) to Encourage People to Evaluate Their Symptoms and Take Charge of Their Health
January 04, 2021 09:00 ET | AuthorHouse
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- The global outbreak of COVID-19 has sparked a lot of healthcare discussions as many people have avoided seeking medical care to ease the strain on...
logo without tag copy (1).png
THC Therapeutics, Inc. Independently Tested, Patented Sanitizing Cannabis Dryer More Relevant Than Ever
December 22, 2020 07:20 ET | THC Therapeutics Inc
The dHydronator’s SanitiZen® technology has been proven to reduce the microbial load level of cannabis from failing laboratory testing and brings the contaminants down to passing levels. THC...
EIB supports AB Science in its COVID-19 development programme
November 30, 2020 00:56 ET | AB Science
Paris, 30 November 2020, 7am  EIB supports AB Science in its COVID-19 development programme Financing deal worth €15.0 million signed to support clinical development programme for masitinibMasitinib...